MMP9 and periodontitis: However, SDD (20 mg twice daily) circumvents these issues—sustaining MMP-9 suppression via non-bactericidal mechanisms, with an FDA-approved indication for chronic use in periodontitis and rosacea and a long-standing record of microbiologic safety and systemic tolerability.